Stephen J. DiPalma, CFO for Worcester-based RXi Pharmaceuticals Corp., and Michael Henry, vice president of business development at Athena Diagnostics Inc. of Worcester, will join the board of directors of Acton-based Neuroptix Corp.
Neuroptix specializes in developing tests for Alzheimer’s Disease.
RXi was co-founded by 2006 Nobel Prize winner Craig Mello. Athena Diagnostics is a specialty brand of Waltham-based Thermo Fisher Scientific.
The duo will help Neuroptix move its Alzheimer’s diagnostic technology into clinical trials, said Paul Hartung, president and CEO of Neuroptix.
